Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids.
Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ Jr, Feltmate CM, Nucci MR, Swisher EM, Nguyen H, Yang C, Morizane R, Kochupurakkal BS, Do KT, Konstantinopoulos PA, Liu JF, Bonventre JV, Matulonis UA, Shapiro GI, Berkowitz RS, Crum CP, D'Andrea AD. Hill SJ, et al. Among authors: horowitz ns. Cancer Discov. 2018 Nov;8(11):1404-1421. doi: 10.1158/2159-8290.CD-18-0474. Epub 2018 Sep 13. Cancer Discov. 2018. PMID: 30213835 Free PMC article.
Management of gestational trophoblastic neoplasia.
Horowitz NS, Goldstein DP, Berkowitz RS. Horowitz NS, et al. Semin Oncol. 2009 Apr;36(2):181-9. doi: 10.1053/j.seminoncol.2008.12.009. Semin Oncol. 2009. PMID: 19332252 Review.
The epidemiology of ovarian granulosa cell tumors: a case-control study.
Boyce EA, Costaggini I, Vitonis A, Feltmate C, Muto M, Berkowitz R, Cramer D, Horowitz NS. Boyce EA, et al. Among authors: horowitz ns. Gynecol Oncol. 2009 Nov;115(2):221-5. doi: 10.1016/j.ygyno.2009.06.040. Epub 2009 Aug 7. Gynecol Oncol. 2009. PMID: 19664811
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT. Matulonis UA, et al. J Clin Oncol. 2009 Nov 20;27(33):5601-6. doi: 10.1200/JCO.2009.23.2777. Epub 2009 Oct 13. J Clin Oncol. 2009. PMID: 19826113 Free PMC article. Clinical Trial.
Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.
Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM. Penson RT, et al. Among authors: horowitz ns. J Clin Oncol. 2010 Jan 1;28(1):154-9. doi: 10.1200/JCO.2009.22.7900. Epub 2009 Nov 16. J Clin Oncol. 2010. PMID: 19917843 Clinical Trial.
Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy.
Rodriguez N, Rauh-Hain JA, Shoni M, Berkowitz RS, Muto MG, Feltmate C, Schorge JO, Del Carmen MG, Matulonis UA, Horowitz NS. Rodriguez N, et al. Among authors: horowitz ns. Gynecol Oncol. 2012 May;125(2):362-6. doi: 10.1016/j.ygyno.2012.02.006. Epub 2012 Feb 12. Gynecol Oncol. 2012. PMID: 22333992
222 results